Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex

29 Oct 2013

Abstract excerpt

BACKGROUND: Breast cancer is the leading cause of cancer death in women living in the western hemisphere. Despite major advances in first-line endocrine therapy of advanced oestrogen receptor (ER)-positive breast cancer, the frequent recurrence of resistant cancer cells represents a serious obstacle to successful treatment. Understanding the mechanisms leading to acquired resistance, therefore, could pave the way...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Estrogen and related hormone effects
Share to Genomics and Chromatin Dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24169358
DOI: 10.1038/bjc.2013.583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complexPMID 24169358Read ↗

VGLL1 drives therapy resistance in estrogen receptor positive breast cancerSemantic proximity Read ↗

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancerSemantic proximity Read ↗

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.Semantic proximity Read ↗

Metabolic Switch in Endocrine Resistant Estrogen Receptor Positive Breast CancerSemantic proximity Read ↗

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSemantic proximity Read ↗

Association of tamoxifen resistance and lipid reprogramming in breast cancerSemantic proximity Read ↗

Widespread reorganisation of the regulatory chromatin landscape facilitates resistance to inhibition of oncogenic ERBB2 signallingSemantic proximity Read ↗

STAT 1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferationSemantic proximity Read ↗

The impact of Fulvestrant on Estrogen Receptor-Driven Chromatin Dynamics in Breast CancerSemantic proximity Read ↗

Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast CancerSemantic proximity Read ↗

H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferaseSemantic proximity Read ↗

Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.